Enovis (ENOV) Q1 2026 earnings review
Reconstructive Growth Masks Stagnation in P&R
Enovis opened 2026 with a mixed performance: a solid beat on profitability but a clear divergence in segment sales. Total revenue grew 5.4% to $589M, almost entirely carried by the Reconstructive segment's 10.8% growth. Meanwhile, the Prevention & Recovery (P&R) segment ground to a halt, shrinking 0.2% on a reported basis. Despite the top-line drag, the 'One Enovis' execution strategy is bearing fruit on the bottom line. Favorable mix shifts and operational efficiencies drove Adjusted Gross Margin to 62.1% and Adjusted EBITDA to $104M. Management reiterated FY26 guidance, implying they expect organic growth to accelerate and cash flow generation to significantly step up in the coming quarters.
🐂 Bull Case
Adjusted Gross Margin expanded 250 basis points YoY (from 59.6% to 62.1%) under the revised calculation, proving that the shift toward the higher-margin Recon segment and supply chain efficiencies are structurally improving profitability.
The Recon segment continues to take market share, growing 10.8% reported (5.5% organic). International Recon was particularly strong, accelerating to 13.2% reported growth as Lima cross-selling synergies materialize.
🐻 Bear Case
P&R reported growth reversed into negative territory (-0.2%) and organic growth decelerated to a meager 1.0%. The U.S. Other P&R sub-segment collapsed 16.2%, raising questions about the need for further aggressive portfolio pruning.
Despite glowing 'Adjusted' metrics, Enovis still posted an $8.5M Net Loss. Sticky strategic transaction costs ($11M) and high SG&A loads continue to prevent the underlying business health from reaching the actual bottom line.
⚖️ Verdict: ⚪
Neutral. The margin expansion and Recon outperformance are highly encouraging, but the company remains a tale of two segments. Until the P&R segment can be stabilized or divested, the drag on overall top-line momentum is too significant to ignore.
Key Themes
Reconstructive Segment Carrying the Load
Stable. The Recon segment remains Enovis's undisputed growth engine, posting $317M in revenue (+10.8% reported, +5.5% organic). Momentum is underpinned by recent technology introductions like the Nebula Stent and OrthoDrive Impactor, which are driving competitive conversions. International Recon grew an impressive 13.2% reported, showcasing the effectiveness of the post-Lima integration cross-selling.
P&R Segment Grinds to a Halt
Decelerating. After the Dr. Comfort divestiture in late 2025, management claimed the remaining P&R portfolio was healthier. Q1 26 data contradicts this narrative: total P&R revenue dropped 0.2% YoY. The U.S. Other P&R sub-segment was the main culprit, plummeting 16.2% on a reported basis. This persistent weakness suggests management has not yet finished pruning the portfolio to achieve its goal of consistent mid-single-digit growth.
Adjusted Margins Expanding Rapidly
Accelerating. The mix shift toward the Recon segment and the application of the EGX business system are yielding massive improvements in unit economics. Adjusted Gross Margin jumped to 62.1% (from 59.6% a year ago). Adjusted EBITDA margin expanded to 17.6% (from 15.6%), reflecting solid operational discipline and pricing mitigation against supply chain pressures.
Operating Cash Flow Inflection
Reversing. Historically plagued by negative cash flows in the first quarter due to seasonality and integration costs, Enovis posted $24.0M in positive operating cash flow in 26Q1 (up from a $1.6M outflow in 25Q1). This turnaround validates management's renewed focus on working capital execution and provides the necessary capital to drive down leverage.
Sticky Integration Costs Drag on GAAP Earnings
Stable. While adjusted metrics look fantastic, the company reported a GAAP Net Loss of $8.5M. This is a dramatic improvement from the $55.7M loss a year ago, but it exposes the persistent drag of 'one-time' expenses. Specifically, the company booked $11.0M in strategic transaction costs for Lima integration and ERP rationalization. Until these adjustments fade, true profitability remains out of reach.
Macroeconomic and Tariff Headwinds Persist
Stable. Management explicitly flagged dynamic macroeconomic conditions, geopolitical tensions, and the implementation of tariffs as ongoing risks. In 2025, the company faced a gross tariff exposure of $40M (mitigated to $20M net). The fact that tariffs remain a highlighted risk factor indicates that Enovis is still heavily engaged in shifting its supply chain away from exposed regions.
Other KPIs
Increasing 5.1% YoY, roughly in line with reported revenue growth. At 48.0% of total sales, the overhead load remains high. Management must exercise stricter cost control here to allow gross margin expansions to flow purely to the bottom line.
Stable compared to year-end 2025. Made up of $35M in current portion and $1.29B in long-term debt. With cash reserves sitting at just $33.1M, deleveraging continues to be the most critical objective for capital allocation, superseding M&A or buybacks.
Flat at -0.2% YoY. As the largest sub-segment within P&R, its failure to generate growth highlights the broader stagnation facing the legacy non-surgical business.
Guidance
Accelerating. Reiterated. The midpoint of $2.34 billion implies an acceleration to roughly 6.3% YoY growth compared to FY25. Considering Q1 only delivered 3.3% organic growth, management is heavily relying on a strong ramp in the second half of the year, likely driven by the broader Arvis system rollout.
Accelerating. Reiterated. The midpoint of $430 million implies an expansion over FY25's base. It also suggests a full-year margin target of ~18.3%, meaning sequential margin improvement is required from Q1's 17.6%.
Accelerating. Reiterated. Represents strong bottom-line growth over FY25's ~$3.30, validating the leverage in the business model if integration costs and tariffs can be successfully mitigated.
Accelerating. Reiterated. Following a 10% conversion in 2025, this 25%+ target is the next milestone on the company's long-term path to 70-80% conversion. The positive operating cash flow generation in Q1 provides a solid foundation for achieving this.
Key Questions
P&R Segment Drag
With the U.S. Other P&R segment falling 16% and overall P&R flatlining despite the recent Dr. Comfort divestiture, what specific product lines are dragging the segment down, and are further divestitures actively being pursued?
Bridge to Full-Year Guidance
Q1 organic revenue grew 3.3%, yet full-year guidance calls for 4-6%. What gives you confidence in this required acceleration, and how much of it hinges on the timeline of the Arvis augmented reality system rollout?
Strategic Transaction Costs
You recorded $11M in strategic transaction costs this quarter for Lima integration and ERP rationalization. What is the expected timeline for these 'one-time' expenses to fully roll off and allow Adjusted EBITDA margins to translate into GAAP profitability?
Tariff Mitigation Progress
Tariffs were explicitly highlighted as an ongoing risk in the press release. How much of the planned supply chain shift out of China has been completed to date, and what was the specific margin impact of tariffs in Q1?